地衣芽孢杆菌活菌联合双歧杆菌三联活菌治疗老年慢性腹泻的临床研究  

Clinical Study on the Treatment of Chronic Diarrhea in the Elderly with Live Bacillus Licheniformis Combined with Bifidobacterium Triple Live Bacteria

作　　者：黄晓春 蒋大丽 顾建祥 Huang Xiaochun;Jiang Dali;Gu Jianxiang(Digestive Department,Second People's Hospital of Huai'an City,Huai'an,Jiangsu,223001,P.R.China)

机构地区：[1]淮安市第二人民医院(徐州医科大学附属淮安医院)消化科,江苏淮安223001

出　　处：《老年医学与保健》2020年第2期258-261,共4页Geriatrics & Health Care

摘　　要：目的探讨地衣芽孢杆菌活菌联合双歧杆菌三联活菌治疗老年慢性腹泻的临床价值。方法选取2016年7月-2019年4月淮安市第二人民医院住院的老年慢性腹泻患者122例,随机分为观察组和对照组,每组61例。对照组予以双歧杆菌三联活菌,观察组采用地衣芽孢杆菌活菌联合双歧杆菌三联活菌治疗。评估并比较2组治疗有效率、腹泻分级、肠黏膜屏障功能(内毒素和D-乳酸)、肠道菌群(乳酸杆菌、双歧杆菌、粪肠球菌和大肠杆菌)和不良反应发生率。结果观察组治疗总有效率明显高于对照组(90.16%vs 75.41%,P<0.05);治疗后观察组腹泻分级明显低于对照组(P<0.05);观察组治疗后血清内毒素和D-乳酸水平明显低于对照组[(0.28±0.03)EU/mL vs(0.35±0.06)EU/mL;(8.97±0.9)mg/L vs(12.68±1.36)mg/L;P<0.05];观察组治疗后大便中乳酸杆菌和双歧杆菌含量高于对照组[(6.94±0.67)CFU/g vs(6.67±0.68)CFU/g;(9.12±0.94)CFU/g vs(8.77±0.88)CFU/g;P<0.05],而粪肠球菌和大肠杆菌含量[(6.34±0.68)CFU/g vs(6.72±0.65)CFU/g;(6.73±0.67)CFU/g vs(7.01±0.72)CFU/g;P<0.05];2组不良反应发生率比较差异无统计学意义(13.11%vs 9.84%,P>0.05)。结论地衣芽孢杆菌活菌联合双歧杆菌三联活菌治疗老年慢性腹泻疗效较好,可明显减轻腹泻,改善患者肠黏膜屏障功能及肠道菌群,且安全性好。Objective To study the clinical values of live bacillus licheniformis combined with bifidobacterium triple live bacteria in the treatment of chronic diarrhea in the elderly. Methods From July 2016 to April 2019, 122 elderly patients with chronic diarrhea in our hospital were selected and divided randomly into the observation group and control group. The control group was treated with bifidobacterium triple viable organisms and the observation group was treated with live bacillus licheniformis combined with bifidobacterium triple viable organisms. The effective rate of treatment, diarrhea grade, intestinal mucosal barrier function(endotoxin, D-lactic acid), intestinal flora(lactobacillus, bifidobacterium, Enterococcus faecalis, Escherichia coli) and the incidence of adverse reactions were compared between the two groups. Results The effective rate of the observation group was higher than that of the control group(90.16% vs 75.41%)(P<0.05). After the treatment, the diarrhea grade of the observation group was lower than that of the control group(P<0.05);the levels of serum endotoxin(0.28±0.03 EU/mL) and D-lactic acid(8.97±0.9 mg/L) of the observation group were lower than those of the control group(0.35±0.06 EU/mL and12.68±1.36 mg/L)(P<0.05);the contents of Lactobacillus(6.94±0.67 CFU/g) and Bifidobacterium(9.12±0.94 CFU/g) in the stool were higher than those in the control group(6.67±0.68 and 8.77±0.88 CFU/g), the Enterococcus faecalis(6.34±0.68)and Escherichia coli(6.73±0.67) in the stool were lower than those in the control group(6.72±0.65 and 7.01±0.72 CFU/g)(P<0.05). There was no significant difference in the incidence of the adverse reactions between the two groups(13.11% vs 9.84%,P>0.05). Conclusions Living bacillus licheniformis combined with bifidobacterium triple viable organisms is effective in the treatment of chronic diarrhea in the elderly, and it can significantly reduce diarrhea, improve the intestinal mucosal barrier function and intestinal flora of the patients, and has good safety.

关 键 词：老年 慢性腹泻 地衣芽孢杆菌 双歧杆菌三联 

分 类 号：R574.62[医药卫生—消化系统]